AGIOS PHARMACEUTICALS, INC. — fact timeline

AGIOS PHARMACEUTICALS, INC. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm.

“4. The Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the current fiscal year. The results of the stockholders’ vote with respect to such ratification were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 48,511,213 116,938 15,376 0”

AGIOS PHARMACEUTICALS, INC. shareholders approved Approval of the 2023 Plan Amendment.

“3. The Company’s stockholders approved the 2023 Plan Amendment. The results of the stockholders’ vote with respect to the approval of the 2023 Plan Amendment were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 43,549,751 2,527,678 11,651 2,554,446”

AGIOS PHARMACEUTICALS, INC. shareholders approved Non-binding advisory vote on compensation paid to named executive officers.

“2. The Company’s stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers. The results of the stockholders’ non-binding, advisory vote with respect to compensation paid to the Company’s named executive officers were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 43,396,045 1,086,059 1,606,976 2,554,446”

AGIOS PHARMACEUTICALS, INC. shareholders approved Election of Class I Directors.

“1. The Company’s stockholders elected Rahul Ballal, Ph.D., Brian Goff and Cynthia Smith as Class I directors, each to serve for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified. The results of the stockholders’ vote with respect to the election of such Class I directors were as follows: Votes For Votes Withheld Broker Non-Votes Rahul Ballal, Ph.D. 40,145,081 5,943,999 2,554,446 Brian Goff 45,757,238 331,843 2,554,446 Cynthia Smith 31,496,376 14,592,704 2,554,446”

AGIOS PHARMACEUTICALS, INC. reported the quarter ended March 31, 2026 results: net income $99.1 million.

“For the quarter ended March 31, 2026, net loss was $99.1 million, compared to net loss of $89.3 million for the quarter ended March 31, 2025.”

David P. Schenkein, M.D. resigned as Director at AGIOS PHARMACEUTICALS, INC..

“On February 10, 2025, David P. Schenkein, M.D., notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), effective February 28, 2025.”

AGIOS PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2024 results: revenue $8.2 million.

“RISE UP Study in Sickle Cell Disease, ACTIVATE-KIDS and ACTIVATE KIDS-T in Pediatric PK Deficiency, All Expected by End of 2025 – – PYRUKYND® (Mitapivat) Net Revenue of $8.2 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $714.3 Million as of March 31, 2024 – CAMBRIDGE, Mass., May 2, 2024 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a”

AGIOS PHARMACEUTICALS, INC. reported financial results for the fourth quarter and year ended December 31, 2023.

“On February 15, 2024, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter and year ended December 31, 2023 and other business highlights.”

AGIOS PHARMACEUTICALS, INC. reported third quarter ended September 30, 2023 results: revenue $7.4 million, net income $91.3 million net loss.

“Data Readouts in Two Phase 3 Trials of Mitapivat in Thalassemia Next Year and Topline Data for AG-946 in LR-MDS by Year-end 2023 – – U.S. PYRUKYND ® (mitapivat) Net Revenue of $7.4 Million in Q3; Cash, Cash Equivalents and Marketable Securities of $872.4 Million as of September 30, 2023 – CAMBRIDGE, Mass., November 2, 2023 -- Agios Pharmaceuticals, Inc. (Nasdaq:”

AGIOS PHARMACEUTICALS, INC. reported the second quarter ended June 30, 2023 results: revenue $6.7 million, net income $83.8 million.

“License Agreement with Alnylam Pharmaceuticals to License Alnylam’s Novel siRNA for the Potential Treatment of Polycythemia Vera – U.S. PYRUKYND ® (mitapivat) Net Revenue of $6.7 Million in Q2; $947 Million of Cash, Cash Equivalents and Marketable Securities as of June 30, 2023 CAMBRIDGE, Mass., August 3, 2023 -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a”

AGIOS PHARMACEUTICALS, INC. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2023-04-26 meeting.

“The Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the current fiscal year.”

AGIOS PHARMACEUTICALS, INC. shareholders approved Approval of the 2023 Plan at the 2023-04-26 meeting.

“The Company’s stockholders approved the 2023 Plan.”

AGIOS PHARMACEUTICALS, INC. shareholders approved Non-binding advisory vote on compensation paid to named executive officers at the 2023-04-26 meeting.

“The Company’s stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”

AGIOS PHARMACEUTICALS, INC. shareholders approved Election of Class I directors at the 2023-04-26 meeting.

“The Company’s stockholders elected Rahul Ballal, Brian Goff and Cynthia Smith as Class I directors, each to serve for a three-year term expiring at the 2026 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified.”

Kaye Foster was appointed as Lead Independent Director at AGIOS PHARMACEUTICALS, INC..

“appointed director Kaye Foster to serve as the Board’s lead independent director”

Catherine Owen was elected as Director at AGIOS PHARMACEUTICALS, INC..

“elected Catherine Owen as a director, effective as of June 13, 2023”

John Maraganore resigned as Director at AGIOS PHARMACEUTICALS, INC..

“John Maraganore, Ph.D., notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), effective May 24, 2023”

AGIOS PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2023 results: revenue $5.6 million, net income $81.0 million.

“Phase 2 Portion of the RISE UP Study in Sickle Cell Disease in Mid-2023 and the Phase 3 ENERGIZE and ENERGIZE-T Studies in Thalassemia in 2024 • U.S. PYRUKYND ® Net Revenue of $5.6 Million in Q1; $1.0 Billion of Cash, Cash Equivalents and Marketable Securities as of March 31, 2023 CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc.”

Jeff Capello was elected as Director at AGIOS PHARMACEUTICALS, INC..

“On April 18, 2023, the Board of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Corporate Governance Committee”), elected Jeff Capello as a director, effective as of the date of the Corporation’s 2023 Annual Meeting of Stockholders (the “Effective Date”).”

Paul Clancy resigned as Director at AGIOS PHARMACEUTICALS, INC..

“On April 17, 2023, Paul Clancy notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision not to stand for re-election to the Board of Directors (the “Board”) of the Company when his current term expires at the Company’s 2023 Annual Meeting of Stockholders.”

AGIOS PHARMACEUTICALS, INC.: Amended and restated the bylaws to update procedural mechanics and disclosure requirements for stockholder nominations and proposals, among other changes (effective 2023-03-02).

“On March 2, 2023, the Board of Directors (the “Board”) of Agios Pharmaceuticals, Inc. (the “Company”) approved an amendment and restatement of the Company’s Second Amended and Restated By-Laws (as so amended and restated, the “Third Amended and Restated By-Laws”), effective immediately.”

AGIOS PHARMACEUTICALS, INC. reported the fourth quarter and year ended Dec. 31, 2022 results: revenue Net U.S. product revenue from sales of PYRUKYND® was $4.3 million for the fourth quarter of 2022, and $11.7 million for, net income Net income was $36.5 million for the fourth quarter of 2022 compared to a net loss of $98.6 million for the fourth quart.

“Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today reported business highlights and financial results for the fourth quarter and year ended Dec. 31, 2022.”

Tsveta Milanova was appointed as Chief Commercial Officer at AGIOS PHARMACEUTICALS, INC..

“the Company appointed Tsveta Milanova as the Company’s Chief Commercial Officer, effective as of January 3, 2023”

AGIOS PHARMACEUTICALS, INC. reported third quarter ended September 30, 2022 results: revenue $3.5 million, net income Net loss from continuing operations was $81.7 million.

“Quarter 2022 Financial Results – U.S. PYRUKYND ® (mitapivat) Launch Provides Capability Building Platform to Support Expected Future Product Growth and Expansion; Net Revenue of $3.5 Million in Q3 – – Received Positive CHMP Opinion for PYRUKYND ® in Adults with Pyruvate Kinase (PK) Deficiency – – On Track to Meet Year-end Enrollment Targets in PYRUKYND ® Thalassemia”

AGIOS PHARMACEUTICALS, INC. entered into Purchase and Sale Agreement with Sagard Healthcare Royalty Partners, LP, Sagard Healthcare Partners Co-Invest Designated Activity Company valued at $131,783,241 (effective 2022-10-27).

“On October 27, 2022, Agios Pharmaceuticals, Inc. (the “Company”) entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Sagard Healthcare Royalty Partners, LP, a Cayman Islands exempt limited partnership, and Sagard Healthcare Partners Co-Invest Designated Activity Company, a company incorporated in Ireland, as purchasers (together, the “Purchasers”), and Sagard Healthcare Royalty Partners, LP, a Cayman Islands exempt limited partnership, as the Purchaser’s representative.”

Cecilia Jones was appointed as Chief Financial Officer at AGIOS PHARMACEUTICALS, INC..

“On September 15, 2022, the Board of Directors (the “Board”) of Agios Pharmaceuticals, Inc. (the “Company”) appointed Cecilia Jones as the Company’s Chief Financial Officer effective as of September 26, 2022 (the “Effective Date”).”

Jonathan Biller resigned as Chief Financial Officer at AGIOS PHARMACEUTICALS, INC..

“On September 6, 2022, Jonathan Biller notified the Company of his intention to resign as chief financial officer, head of corporate affairs and principal financial officer of the Company, effective September 16, 2022, in order to pursue other opportunities.”

Cynthia Smith was elected as director at AGIOS PHARMACEUTICALS, INC..

“On August 11, 2022, the Board of Directors (the “Board”) of Agios Pharmaceuticals, Inc. (the “Company”), upon the recommendation of the Board’s Nominating and Corporate Governance Committee (the “Corporate Governance Committee”), elected Rahul Ballal, Ph.D. and Cynthia Smith as directors.”

Rahul Ballal was elected as director at AGIOS PHARMACEUTICALS, INC..

“On August 11, 2022, the Board of Directors (the “Board”) of Agios Pharmaceuticals, Inc. (the “Company”), upon the recommendation of the Board’s Nominating and Corporate Governance Committee (the “Corporate Governance Committee”), elected Rahul Ballal, Ph.D. and Cynthia Smith as directors.”

Brian Goff was appointed as Chief Executive Officer at AGIOS PHARMACEUTICALS, INC..

“the Board appointed Brian Goff as the Company’s Chief Executive Officer and as a member of the Board”

Jacqualyn A. Fouse changed role as Chair of the Board at AGIOS PHARMACEUTICALS, INC..

“Jacqualyn A. Fouse, Ph.D. will resign from the position of Chief Executive Officer and will assume the role of Chair of the Board of Directors”

Bruce Car resigned as Chief Scientific Officer at AGIOS PHARMACEUTICALS, INC..

“the effective date of Dr. Car’s resignation as the Company’s chief scientific officer”

Bruce Car resigned as chief scientific officer at AGIOS PHARMACEUTICALS, INC..

“On May 15, 2022, Bruce Car, Ph.D. notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision to resign as chief scientific officer of the Company, effective July 31, 2022.”

Ian T. Clark resigned as Director at AGIOS PHARMACEUTICALS, INC..

“On April 25, 2022, Ian T. Clark notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision to resign as a member of the Board, effective immediately following the 2022 annual meeting of stockholders.”

T.J. Washburn was appointed as principal accounting officer at AGIOS PHARMACEUTICALS, INC..

“On August 1, 2021, Agios Pharmaceuticals, Inc. (the “Company”) appointed T.J. Washburn, senior director, corporate accounting of the Company, to serve as the Company’s principal accounting officer.”

Christopher Bowden resigned as chief medical officer at AGIOS PHARMACEUTICALS, INC..

“On July 27, 2021, Christopher Bowden notified the Company of his intention to resign as chief medical officer of the Company, effective September 1, 2021.”